France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway (Infertility Diagnostics, Punction, and Treatment Monitoring) and End User (Public Hospital with Infertility Department, Private Fertility Clinics and Ambulatory Centers): Opport

France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway (Infertility Diagnostics, Punction, and Treatment Monitoring) and End User (Public Hospital with Infertility Department, Private Fertility Clinics and Ambulatory Centers): Opportunity Analysis and Industry Forecast, 2021–2030

The France ultrasound infertility diagnosis and treatment market was valued at $336.54 million in 2020, and is estimated to reach $522.36 million by 2030, growing at a CAGR of 4.4% from 2021 to 2030.

Infertility in individuals is defined as the inability of the male or female reproductive system to conceive naturally. Ultrasound-guided infertility diagnosis is a technique in which ultrasound waves are used for determination for the cause of infertility in males as well as females. In females, infertility is caused majorly due to blocked fallopian tubes; sexually transmitted infections (STIs); uterine disorders such as endometriosis, septate uterus, and fibroids; and ovarian disorder such as the polycystic ovarian syndrome (PCOS). On the contrary, in males, obstruction of the reproductive tract, testicular impairment, and hormonal misbalance may result in infertility.

Fertility services help treat infertility in men and women. The different forms of fertility treatments available include in vitro fertilization (IVF), fertility testing, intrauterine insemination, and egg freezing & embryo banking. These treatments are often opted by single mothers, the LGBTQ community, and couples who find it hard to procreate. Ultrasound-guided procedures for infertility diagnosis such as hysterosonography, hysterosonosalpyngography, and hysterosalpingo-foam sonography are used to determine the woman's uterus for a variety of issues such as vaginal bleeding, recurrent miscarriages, fibroids, polyps, scar tissue, or other abnormalities.

Hysterosonosalpyngography is used to determine the fallopian tubes blockage. Ultrasound-guided trans-vaginal needle aspiration/biopsy and core-needle testicular biopsy in females and males are the minimally invasive techniques that assess infertility diagnosis. Treatment monitoring service such as the ovulation monitoring is one of the majorly used techniques for predicting the ovulation for conceiving through kits and is less expensive.

The major factors that drive the growth of the ultrasound infertility diagnosis & treatment market include increase in prevalence of infertility rates, rise in trend of delayed pregnancies, surge in the number of median age of first-time mothers, increase in awareness of in vitro fertilization (IVF), and technological advancements for infertility diagnosis. According to the World Bank fertility rate, total (births per woman) in France in 2018 was 1.88, and it reduced to 1.87 in 2019. Infertility affects millions of people of reproductive age worldwide and has an impact on their families and communities. Millions of people of reproductive age around the world are affected by infertility, which has an impact on their families and communities. Thus, increase in infertility rates and reduction of birth rates is expected to drive the market growth.

In addition, surge in adoption of sedentary lifestyle; rise in alcohol, smoking, & tobacco consumption; excessive stress; unhealthy lifestyle; and surge in obesity cases are expected to drive the growth of the ultrasound-guided infertility diagnosis & treatment monitoring services market. For instance, in 2019, according to the World Health Organization (WHO) global report on trends in prevalence of tobacco use 2000–2025, the tobacco use rates across the people in France aged 15 years and older, was estimated to be 36.0 in males and 33.2 in males.

Cigarette smoking rates were estimated to be 33.0 in males and 30.0 in females and about 30.9 in 2018. Thus, such high tobacco consumption and smoking is expected to affect the fertility of males and females, which, in turn, drives the growth of the market in France.

Moreover, according to the Organisation for Economic Co-operation and Development (OECD), about 1 in 10 individuals is obese in France, and almost 40% are overweight (including obese). OECD has estimated that overweight rates will increase by a further 10% within 10 years. In addition, according to the Eurostat in 2019, about 40% of French women were overweight, and among this, about 17% of women were obese. ,. Menstrual disorders and anovulation are more common in overweight women. Women who are overweight or obese are at a higher risk of having a miscarriage. These women have a higher risk of subfecundity and infertility as well as conception, miscarriage, and pregnancy problems. Thus, all these factors notably contribute toward the growth of the France ultrasound infertility diagnosis and treatment market.

Furthermore, technological advancements IVF techniques and frozen embryo transfer boost the market growth. For instance, in June 2021, France’s Lower House of Parliament approved a law that will allow single women and lesbians to access medically assisted reproduction for the first time. Thus, provision of access to fertility treatments such as artificial insemination and IVF is expected to strengthen the growth of the market in France.

However, high cost of infertility diagnosis procedures, risk associated after IVF procedure, and high cost of assisted reproductive technology hinder the market growth. On the contrary, initiatives taken by governments for development of the technology sector in infertility and increase in disposable income level of consumers are expected to offer remunerative opportunities for the market growth.

In addition, surge in demand for advanced technologies in healthcare to enhance efficiency of procedures and smooth delivery of babies is expected to open new avenues for the market growth during the forecast period.

The France ultrasound infertility diagnosis and treatment market is segmented into care pathway and end user. On the basis of care pathway, the market is fragmented into infertility diagnostics, punction, and treatment monitoring. The infertility diagnostics segment is further classified into hysterosonography, hysterosonosalpyngography, and hysterosalpingo-foam sonography (HyFoSy). The punction segment is subsegmented into ultrasound-guided trans-vaginal needle aspiration/biopsy and ultrasound guided core-needle testicular biopsy. Moreover, the treatment monitoring segment comprises frozen embryo transfer services and ovulation monitoring.

Depending on end user, the market is segregated into public hospital with infertility department, private fertility clinics and ambulatory centers. Each end user is further segmented into the care pathway bifurcation of infertility diagnostics, punction, and treatment monitoring.

The major players profiled in the report are American Hospital of Paris, Amp Center St Roch, Amp Natecia Lyon, Centre Chirugical (Pierre Cherest Clinic), Fertility Center-Parsi East, Hospital Cochin, Hospital Group Diaconesses Croix Saint-Simon, Maternité Des Bluets - Hospital Pierre Rouquès, Pointgyn-Pleasure and Ramsay Healthcare Limited (Clinique De La Muette).

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the France ultrasound infertility diagnosis and treatment market to identify the prevailing opportunities.
This study presents the competitive landscape of the market to predict the competitive environment across the country.
Comprehensive analysis of factors that drive and restrict the market growth is provided.

KEY MARKET SEGMENTS


By Care Pathways

Infertility Diagnostics
Hysterosonography
Hysterosonosalpyngography
Hysterosalpingo-foam Sonography (HyFoSy)
Punction
Ultrasound-guided trans-vaginal Needle Aspiration/Biopsy
Ultrasound-guided core-needle Testicular Biopsy
Treatment Monitoring
Frozen Embryo Transfer
Ovulation Monitoring

By End User

Public Hospital with Infertility Department
Infertility Diagnostics
Punction
Treatment Monitoring
Private Fertility Clinics
Infertility diagnostics
Punction
Treatment Monitoring
Ambulatory Centers
Infertility Diagnostics
Punction
Treatment Monitoring

KEY MARKET PLAYERS

American Hospital of Paris
Amp Center St Roch
Amp Natecia Lyon
Centre Chirugical (Pierre Cherest Clinic)
Fertility Center-Parsi East
Hospital Cochin
Hospital Group Diaconesses Croix Saint-Simon
Maternité Des Bluets - Hospital Pierre Rouquès
Pointgyn-Pleasure
Ramsay Healthcare Limited (Clinique De La Muette)


List of Company Profiles

American Hospital of Paris
Amp Center St Roch
Amp Natecia Lyon
Centre Chirugical (Pierre Cherest Clinic)
Fertility Center-Parsi East
Hospital Cochin
Hospital Group Diaconesses Croix Saint-Simon
Maternité Des Bluets - Hospital Pierre Rouquès
Pointgyn-Pleasure,
Ramsay Healthcare Limited (Clinique De La Muette).

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profile in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Top player positioning, 2020
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in infertility rate
3.4.1.2.Delayed pregnancies
3.4.1.3.Technological advancements in ultrasound-guided infertility diagnosis
3.4.1.4.Increase in disposable income and rise in awareness regarding infertility treatment
3.4.2.Restraint
3.4.2.1.High cost for infertility diagnosis and treatment
3.4.3.Opportunity
3.4.3.1.Rise in trend of fertility tourism
3.4.4.Impact analysis
3.5.Impact analysis of COVID-19 on the market
3.6.Company profiles of ultrasound providers in infertility diagnosis and treatment market
3.6.1.CANON INC. (CANON MEDICAL SYSTEMS CORPORATION)
3.6.1.1.Company overview
3.6.1.2.Company snapshot
3.6.1.3.Operating business segments
3.6.1.4.Product portfolio
3.6.1.5.Business performance
3.6.2.GENERAL ELECTRIC COMPANY (GE HEALTHCARE)
3.6.2.1.Company overview
3.6.2.2.Company snapshot
3.6.2.3.Operating business segments
3.6.2.4.Product portfolio
3.6.2.5.Business performance
3.6.2.6.Key strategic moves and developments
3.6.3.KONINKLIJKE PHILIPS N.V
3.6.3.1.Company overview
3.6.3.2.Company snapshot
3.6.3.3.Operating business segments
3.6.3.4.Product portfolio
3.6.3.5.Business performance
3.6.3.6.Key strategic moves and developments
3.6.4.MINDRAY MEDICAL INTERNATIONAL LIMITED
3.6.4.1.Company overview
3.6.4.2.Company snapshot
3.6.4.3.Operating business segments
3.6.4.4.Product portfolio
3.6.5.SIEMENS AG
3.6.5.1.Company overview
3.6.5.2.Company snapshot
3.6.5.3.Operating business segments
3.6.5.4.Product portfolio
3.6.5.5.Business performance
3.6.5.6.Key strategic moves and developments
CHAPTER 4:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY
4.1.Overview
4.1.1.Market size and forecast
4.2.Infertility diagnostics
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Hysterosonography
4.2.2.1.1.Market size and forecast
4.2.2.2.Hysterosonosalpyngography
4.2.2.2.1.Market size and forecast
4.2.2.3.Hysterosalpingo-foam sonography (HyFoSy)
4.2.2.3.1.Market size and forecast
4.3.Punction
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Ultrasound-guided trans-vaginal needle aspiration/biopsy
4.3.2.1.1.Market size and forecast
4.3.2.2.Ultrasound-guided core-needle testicular biopsy
4.3.2.2.1.Market size and forecast
4.4.Treatment monitoring
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Frozen embryo transfer
4.4.2.1.1.Market size and forecast
4.4.2.2.Ovulation monitoring
4.4.2.2.1.Market size and forecast
CHAPTER 5:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Public hospital with infertility department
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by care pathway
5.2.2.1.Infertility diagnostics
5.2.2.1.1.Market size and forecast
5.2.2.2.Punction
5.2.2.2.1.Market size and forecast
5.2.2.3.Treatment monitoring
5.2.2.3.1.Market size and forecast
5.3.Private fertility clinics
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by care pathway
5.3.2.1.Infertility diagnostics
5.3.2.1.1.Market size and forecast
5.3.2.2.Punction
5.3.2.2.1.Market size and forecast
5.3.2.3.Treatment monitoring
5.3.2.3.1.Market size and forecast
5.4.Ambulatory centers
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by care pathway
5.4.2.1.Infertility diagnostics
5.4.2.1.1.Market size and forecast
5.4.2.2.Punction
5.4.2.2.1.Market size and forecast
5.4.2.3.Treatment monitoring
5.4.2.3.1.Market size and forecast
CHAPTER 6:COMPANY PROFILES
6.1.AMERICAN HOSPITAL 0F PARIS
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product portfolio
6.2.AMP CENTER ST ROCH
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Operating business segments
6.2.4.Product portfolio
6.3.AMP NATECIA LYON
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio
6.4.CENTRE CHIRUGICAL (PIERRE CHEREST CLINIC)
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Operating business segments
6.4.4.Product portfolio
6.5.FERTILITY CENTER-PARSI EAST
6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio
6.6.HOSPITAL COCHIN
6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Operating business segments
6.6.4.Product portfolio
6.7.HOSPITAL GROUP DIACONESSES CROIX SAINT-SIMON
6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio
6.8.MATERNITÉ DES BLUETS - HOSPITAL PIERRE ROUQUÈS
6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Operating business segment
6.8.4.Product portfolio
6.9.POINTGYN - PLEASURE
6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Operating business segments
6.9.4.Product portfolio
6.10.RAMSAY HEALTHCARE LIMITED (CLINIQUE DE LA MUETTE)
6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product portfolio
6.10.5.Business performance
LIST OF TABLES
TABLE 01.CANON: COMPANY SNAPSHOT
TABLE 02.CANON: OPERATING SEGMENTS
TABLE 03.CANON: PRODUCT PORTFOLIO
TABLE 04.GE: COMPANY SNAPSHOT
TABLE 05.GE: PRODUCT SEGMENTS
TABLE 06.GE: PRODUCT PORTFOLIO
TABLE 07.GE: KEY DEVELOPMENTS
TABLE 08.PHILIPS: COMPANY SNAPSHOT
TABLE 09.PHILIPS: PRODUCT SEGMENTS
TABLE 10.PHILIPS: PRODUCT PORTFOLIO
TABLE 11.PHILIPS: KEY DEVELOPMENTS
TABLE 12.MINDRAY: COMPANY SNAPSHOT
TABLE 13.MINDRAY: OPERATING SEGMENTS
TABLE 14.MINDRAY: PRODUCT PORTFOLIO
TABLE 15.SIEMENS: COMPANY SNAPSHOT
TABLE 16.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 17.SIEMENS: PRODUCT PORTFOLIO
TABLE 18.SIEMENS: KEY DEVELOPMENTS
TABLE 19.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 20.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, BY TYPE, 2020–2030 ($MILLION)
TABLE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, BY TYPE, 2020–2030($MILLION)
TABLE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, BY TYPE, 2020–2030 ($MILLION)
TABLE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUBLIC HOSPITAL WITH INFERTILITY DEPARTMENT, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PRIVATE FERTILITY CLINICS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR AMBULATORY CENTERS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 27.AMERICAN HOSPITAL: COMPANY SNAPSHOT
TABLE 28.AMERICAN HOSPITAL: OPERATING SEGMENT
TABLE 29.AMERICAN HOSPITAL: PRODUCT PORTFOLIO
TABLE 30.ST ROCH: COMPANY SNAPSHOT
TABLE 31.ST ROCH: OPERATING SEGMENTS
TABLE 32.ST ROCH: PRODUCT PORTFOLIO
TABLE 33.NATECIA: COMPANY SNAPSHOT
TABLE 34.NATECIA: OPERATING SEGMENTS
TABLE 35.NATECIA: PRODUCT PORTFOLIO
TABLE 36.CHIRUGICAL: COMPANY SNAPSHOT
TABLE 37.CHIRUGICAL: OPERATING SEGMENT
TABLE 38.CENTRE CHIRUGICAL: PRODUCT PORTFOLIO
TABLE 39.FERTILITY CENTER: COMPANY SNAPSHOT
TABLE 40.FERTILITY CENTER: OPERATING SEGMENT
TABLE 41.FERTILITY CENTER: PRODUCT PORTFOLIO
TABLE 42.COCHIN: COMPANY SNAPSHOT
TABLE 43.COCHIN: OPERATING SEGMENTS
TABLE 44.COCHIN: PRODUCT PORTFOLIO
TABLE 45.DIACONESSES: COMPANY SNAPSHOT
TABLE 46.DIACONESSES: OPERATING SEGMENT
TABLE 47.DIACONESSES: PRODUCT PORTFOLIO
TABLE 48.BLUETS: COMPANY SNAPSHOT
TABLE 49.BLUETS: OPERATING SEGMENTS
TABLE 50.BLUETS: PRODUCT PORTFOLIO
TABLE 51.POINTGYN: COMPANY SNAPSHOT
TABLE 52.POINTGYN: OPERATING SEGMENT
TABLE 53.POINTGYN: PRODUCT PORTFOLIO
TABLE 54.RAMSAY: COMPANY SNAPSHOT
TABLE 55.RAMSAY: OPERATING SEGMENTS
TABLE 56.RAMSAY: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION
FIGURE 02.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTES
FIGURE 05.HIGH THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE INTENSITY OF RIVALRY
FIGURE 07.TOP PLAYER POSITIONING, 2020
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.CANON: NET SALES, 2018–2020 ($MILLION)
FIGURE 10.CANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.CANON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 12.GE: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.GE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 14.GE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 15.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 16.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 18.SIEMENS: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.SIEMENS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOGRAPHY, 2020–2030 ($MILLION)
FIGURE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOSALPYNGOGRAPHY , 2020–2030 ($MILLION)
FIGURE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYFOSY, 2020–2030 ($MILLION)
FIGURE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED TRANS-VAGINAL NEEDLE ASPIRATION/BIOPSY, 2020–2030 ($MILLION)
FIGURE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED CORE-NEEDLE TESTICULAR BIOPSY, 2020–2030 ($MILLION)
FIGURE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR FROZEN EMBRYO TRANSFER, 2020–2030 ($MILLION)
FIGURE 27.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR OVULATION MONITORING, 2020–2030 ($MILLION)
FIGURE 28.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 29.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 30.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 31.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 32.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 33.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 34.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 35.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 36.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 37.RAMSAY: NET SALES, 2019–2021 ($MILLION)
FIGURE 38.RAMSAY: REVENUE SHARE, BY SEGMENT, 2021 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings